NASDAQ:TBPH

Theravance Biopharma - TBPH Stock Forecast, Price & News

$10.03

-0.13 (-1.28%)

(As of 09/29/2022 12:39 PM ET)

Add

Compare

Today's Range: $10.00
▼
$10.23
50-Day Range: $8.67
▼
$10.22
52-Week Range: $7.30
▼
$13.17

Volume: 22,787 shs
Average Volume: 584,900 shs
Market Capitalization: $766.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.75

Theravance Biopharma MarketRank™ Forecast

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 16.2% Upside
$11.75 Price Target
Short Interest: Bearish
9.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.04
Based on 6 Articles This Week
Insider Trading: Selling Shares
$180,243 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.77) to ($0.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.41 out of 5 stars

Medical Sector

1058th out of 1,096 stocks

Pharmaceutical Preparations Industry

524th out of 548 stocks

2.1

Analyst's Opinion

Consensus Rating
Theravance Biopharma has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $11.75, Theravance Biopharma has a forecasted upside of 16.2% from its current price of $10.11.
Amount of Analyst Coverage
Theravance Biopharma has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.81% of the outstanding shares of Theravance Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Theravance Biopharma has a short interest ratio ("days to cover") of 7.9.
Change versus previous month
Short interest in Theravance Biopharma has recently decreased by 2.98%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Theravance Biopharma does not currently pay a dividend.
Dividend Growth
Theravance Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TBPH.

2.2

News and Social Media Coverage

News Sentiment
Theravance Biopharma has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Theravance Biopharma this week, compared to 1 article on an average week.
Search Interest
8 people have searched for TBPH on MarketBeat in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Theravance Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $180,243.00 in company stock.
Percentage Held by Insiders
Only 4.80% of the stock of Theravance Biopharma is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Theravance Biopharma are expected to grow in the coming year, from ($0.77) to ($0.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Theravance Biopharma is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Theravance Biopharma is -7.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Stock News Headlines

September 28, 2022 | nasdaq.com

Theravance Biopharma Announces Modified Dutch Auction Tender Offer - Quick Facts

September 28, 2022 | marketwatch.com

Theravance Biopharma Sets $95 Million Stock Tender Offer >TBPH

September 28, 2022 | finance.yahoo.com

Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares

September 21, 2022 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Theravance Biopharma (TBPH)

September 20, 2022 | finance.yahoo.com

Company News for Sep 20, 2022

September 19, 2022 | msn.com

Here's Why Theravance Biopharma Shares Are Moving

September 19, 2022 | finance.yahoo.com

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings

September 19, 2022 | markets.businessinsider.com

Theravance Biopharma Rises 6% On News Of Share Buyback

September 19, 2022 | markets.businessinsider.com

Theravance To Buy Back $250 Mln Of Shares

September 8, 2022 | finance.yahoo.com

Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?

August 16, 2022 | nasdaq.com

Broker Revenue Forecasts For Theravance Biopharma, Inc. (NASDAQ:TBPH) Are Surging Higher

August 14, 2022 | finance.yahoo.com

Need To Know: Analysts Are Much More Bullish On Theravance Biopharma, Inc. (NASDAQ:TBPH) Revenues

August 7, 2022 | seekingalpha.com

Theravance Biopharma, Inc.'s (TBPH) CEO Rick Winningham on Q2 2022 Results - Earnings Call Transcript

August 4, 2022 | finance.yahoo.com

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022 | msn.com

Theravance Biopharma's Earnings: A Preview

July 28, 2022 | finance.yahoo.com

Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022

July 26, 2022 | finance.yahoo.com

Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023

July 26, 2022 | finance.yahoo.com

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

July 16, 2022 | markets.businessinsider.com

Pre-market Movers: ARQQ, RAD, TBPH, ULCC, EGY…

July 14, 2022 | finance.yahoo.com

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests

July 13, 2022 | seekingalpha.com

Royalty Pharma to buy royalty interest in Trelegy drug from Theravance, Innoviva for $1.3B

June 6, 2022 | finance.yahoo.com

Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?

May 23, 2022 | seekingalpha.com

Theravance Biopharma initiated with an Outperform at SVB Leerink

May 13, 2022 | finance.yahoo.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) About To Shift From Loss To Profit

May 7, 2022 | seekingalpha.com

Theravance Biopharma's (TBPH) CEO Rick Winningham on Q1 2022 Results -Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theravance Biopharma and its competitors with MarketBeat's FREE daily newsletter.

TBPH Company Calendar

Last Earnings: 8/04/2022
Today: 9/29/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TBPH
Previous Symbol: NASDAQ:TBPHV
CUSIP: N/A
CIK: 1583107
Web: www.theravance.com
Phone: (650) 808-6000
Fax: N/A
Employees: 359
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.75
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +17.1%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-199,430,000.00
Net Margins: -193.72%
Pretax Margin: -193.03%
Return on Equity: N/A
Return on Assets: -23.76%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.74
Quick Ratio: 4.74

Sales & Book Value

Annual Sales: $55.31 million
Price / Sales: 13.86
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.59) per share
Price / Book: -2.19

Miscellaneous

Outstanding Shares: 76,430,000
Free Float: 72,759,000
Market Cap: $766.59 million
Optionable: Optionable
Beta: 0.66

Key Executives

Rick E. Winningham
Chairman & Chief Executive Officer

Andrew Asa Hindman
Chief Financial Officer & Senior Vice President

Vijay Sabesan
Senior Vice President-Technical Operations

Philip D. Worboys
Senior VP-Research & Translational Science

Bradford J. Shafer
Secretary, Executive VP & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TBPH Stock - Frequently Asked Questions

Should I buy or sell Theravance Biopharma stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TBPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBPH, but not buy additional shares or sell existing shares.
View TBPH analyst ratings or view top-rated stocks.
What is Theravance Biopharma's stock price forecast for 2022?: 4 Wall Street research analysts have issued 1-year target prices for Theravance Biopharma's shares. Their TBPH share price forecasts range from $11.00 to $12.00. On average, they predict the company's share price to reach $11.75 in the next twelve months. This suggests a possible upside of 17.5% from the stock's current price.
View analysts price targets for TBPH or view top-rated stocks among Wall Street analysts.
How have TBPH shares performed in 2022?: Theravance Biopharma's stock was trading at $11.05 at the beginning of the year. Since then, TBPH shares have decreased by 9.5% and is now trading at $10.00.
View the best growth stocks for 2022 here.
When is Theravance Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our TBPH earnings forecast.
How were Theravance Biopharma's earnings last quarter?: Theravance Biopharma, Inc. (NASDAQ:TBPH) released its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. The biopharmaceutical company had revenue of $11.05 million for the quarter, compared to the consensus estimate of $17.47 million. During the same quarter in the previous year, the firm posted ($0.80) earnings per share.

What other stocks do shareholders of Theravance Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Theravance Biopharma investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL), SCYNEXIS (SCYX), Teva Pharmaceutical Industries (TEVA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Idera Pharmaceuticals (IDRA), Pfizer (PFE) and TG Therapeutics (TGTX).
What is Theravance Biopharma's stock symbol?: Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How do I buy shares of Theravance Biopharma?: Shares of TBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Theravance Biopharma's stock price today?: One share of TBPH stock can currently be purchased for approximately $10.00.
How much money does Theravance Biopharma make?: Theravance Biopharma (NASDAQ:TBPH) has a market capitalization of $764.30 million and generates $55.31 million in revenue each year. The biopharmaceutical company earns $-199,430,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.
How many employees does Theravance Biopharma have?: The company employs 359 workers across the globe.
How can I contact Theravance Biopharma?: Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The official website for the company is www.theravance.com. The biopharmaceutical company can be reached via phone at (650) 808-6000 or via email at investor.relations@theravance.com.

This page (NASDAQ:TBPH) was last updated on 9/29/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Theravance Biopharma - TBPH Stock Forecast, Price & News

Theravance Biopharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month